Surface Oncology
Acquired by Coherus BioSciences
Developing next-generation antibody therapies focused on the tumor microenvironment.
Investment Team
Sector
Life SciencesCategory
TherapeuticsStatus
PublicLocation
Cambridge, MAInitial Investment
2014
Developing next-generation antibody therapies focused on the tumor microenvironment.
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface Oncology went public in 2018 (NASDAQ: SURF). The company has since been acquired by Coherus BioSciences and is no longer a publicly traded company. Surface Oncology was acquired in 2023.